The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 4, 1999, Pages 715-718

  Zietman, Anthony L ^a   Zehr, Elizabeth M ^a   Shipley, William U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Prostate; Prostate specific antigen; Radiation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; FOLLOW UP; HUMAN; MALE; PELVIS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RECTUM CANCER; SECRETION;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0032998961     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00484-2     Document Type: Article

References (15)

1. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow up. J Urol. 149:1993;519-523.
2. Landmann C., Hunig R. Prostate specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys. 17:1989;1073-1076.
3. Ritter M.A., Messing E.M., Shanahan T.G., et al. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 10:1992;1208-1217.
4. Willett C.G., Zietman A.L., Shipley W.U., et al. The effect of pelvic radiation therapy on the production of prostatic specific antigen. J Urol. 151:1994;1579-1581.
5. Hanks G.E., Perez C.A., Kozar M., et al. PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated on RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys. 30:1994;289-292.
6. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
7. Stamey T.A., Ferrari M.K., Schmid H.-P. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol. 150:1993;1856-1859.
8. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial PSA value as a predictor of treatment outcome. J Urol. 151:1994;640-645.
9. Zagars G.K., Pollack A., Kavadi K., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
10. Zietman A.L., Tibbs M.K., Dallow K.C., et al. The use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
11. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
12. Brown E.N., McDermott T.J., Bloch K.J., et al. Defining the smallest analyte concentration an immunoassay can measure. Clin Chem. 42:1996;893-899.
13. Zagars G.K., Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;85-89.
14. Duffner P.K., Cohen M.E., Voorhees M.L., et al. Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer. 56:1985;2189-2193.
15. Kinsella T.J., Fraass B.A., Glatstein E. Late effects of radiation therapy in the treatment of Hodgkin's disease. Cancer Treat Rep. 66:1982;991-996.